FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2005;353(7):744.

Previous Volume 348:2386-2395 June 12, 2003 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by DeVita, V. T. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ekert, H. Related Article PubMed Citation

ABSTRACT

Background Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy.

Methods From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped in 1996 owing to inferior results.

Results For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progression were significantly lower with increased-dose BEACOPP than with COPP-ABVD or standard BEACOPP.

Conclusions Increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD.

Source Information

From the First Department of Internal Medicine, University of Cologne, Cologne, Germany (V.D., J.F., M.P., B.L., U.P., H.T.); the Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany (D.H., M.L.); the Canton Hospital, Basel, Switzerland (R.H.); Charité Hospital, Berlin, Germany (B.D.); the Institute of Pathology, University of Würzburg, Würzburg, Germany (H.-K.M.-H.); and the Department of Radiotherapy, University of Munich, Munich, Germany (E.D.).

Address reprint requests to Dr. Diehl at the Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany, or at v.diehl{at}uni-koeln.de.

Full Text of this Article

Related Letters:

A 38-Year History of Natural-Killer-Cell Lymphoma
Schrader C., Janssen D., Kneba M., Lennert K.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:418-419, Jan 22, 2004. Correspondence

This article has been cited by other articles:

• Sieniawski, M., Reineke, T., Josting, A., Nogova, L., Behringer, K., Halbsguth, T., Fuchs, M., Diehl, V., Engert, A. (2008). Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 0: mdn376v2-mdn376 [Abstract] [Full Text]  
• Biasoli, I., Franchi-Rezgui, P., Sibon, D., Briere, J., de Kerviler, E., Thieblemont, C., Levy, V., Gisselbrecht, C., Brice, P. (2008). Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Ann Oncol 0: mdn391v1-mdn391 [Abstract] [Full Text]  
• Mendler, J. H., Kelly, J., Voci, S., Marquis, D., Rich, L., Rossi, R. M., Bernstein, S. H., Jordan, C. T., Liesveld, J., Fisher, R. I., Friedberg, J. W. (2008). Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 0: mdn365v1-mdn365 [Abstract] [Full Text]  
• Re, A., Ferrari, S., Frata, P., Pizzocaro, C., Crippa, C., Tucci, A., Facchetti, F., Grazioli, L., Magrini, S.M., Rossi, G. (2008). Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol 19: 951-957 [Abstract] [Full Text]  
• Doussis-Anagnostopoulou, I. A., Vassilakopoulos, T. P., Thymara, I., Korkolopoulou, P., Angelopoulou, M. K., Siakantaris, M. P., Kokoris, S. I., Dimitriadou, E. M., Kalpadakis, C., Matzouranis, M., Kaklamanis, L., Panayiotidis, P., Kyrtsonis, M.-C., Androulaki, A., Patsouris, E., Kittas, C., Pangalis, G. A. (2008). Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. Clin. Cancer Res. 14: 1759-1766 [Abstract] [Full Text]  
• Brenner, H., Gondos, A., Pulte, D. (2008). Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111: 2977-2983 [Abstract] [Full Text]  
• Sieniawski, M., Reineke, T., Nogova, L., Josting, A., Pfistner, B., Diehl, V., Engert, A. (2008). Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 111: 71-76 [Abstract] [Full Text]  
• Schmitz, N., Dreger, P., Glass, B., Sureda, A. (2007). Allogeneic transplantation in lymphoma: current status. haematol 92: 1533-1548 [Abstract] [Full Text]  
• Savoldo, B., Rooney, C. M., Di Stasi, A., Abken, H., Hombach, A., Foster, A. E., Zhang, L., Heslop, H. E., Brenner, M. K., Dotti, G. (2007). Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110: 2620-2630 [Abstract] [Full Text]  
• Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J. (2007). Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease. JCO 25: 3902-3907 [Abstract] [Full Text]  
• Blumenfeld, Z. (2007). How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12: 1044-1054 [Abstract] [Full Text]  
• Hohaus, S, Giachelia, M, Di Febo, A, Martini, M, Massini, G, Vannata, B, D'Alo', F, Guidi, F, Greco, M, Pierconti, F, Larocca, L., Voso, M., Leone, G (2007). Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 18: 1376-1381 [Abstract] [Full Text]  
• Kuderer, N. M., Dale, D. C., Crawford, J., Lyman, G. H. (2007). Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. JCO 25: 3158-3167 [Abstract] [Full Text]  
• Sieniawski, M., Franklin, J., Nogova, L., Glossmann, J.-P., Schober, T., Nisters-Backes, H., Diehl, V., Josting, A. (2007). Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-Stage Favorable Hodgkin's Lymphoma. JCO 25: 2000-2005 [Abstract] [Full Text]  
• Byrne, B. J., Gockerman, J. P. (2007). Salvage Therapy in Hodgkin's Lymphoma. The Oncologist 12: 156-167 [Abstract] [Full Text]  
• Dann, E. J., Bar-Shalom, R., Tamir, A., Haim, N., Ben-Shachar, M., Avivi, I., Zuckerman, T., Kirschbaum, M., Goor, O., Libster, D., Rowe, J. M., Epelbaum, R. (2007). Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109: 905-909 [Abstract] [Full Text]  
• Brusamolino, E., Carella, A. M. (2007). Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives. haematol 92: 6-10 [Full Text]  
• Horning, S. J. (2007). Risk, Cure and Complications in Advanced Hodgkin Disease. ASH Education Book 2007: 197-203 [Abstract] [Full Text]  
• Venugopal, P., Gregory, S. A. (2007). Lymphoproliferative disorders. ASH-SAP 2007: 265-297 [Full Text]  
• Ng, A., Mauch, P. (2006). The impact of treatment on the risk of second malignancy after Hodgkin's disease. Ann Oncol 17: 1727-1729 [Full Text]  
• Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., Khanna, R. (2006). Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108: 2280-2289 [Abstract] [Full Text]  
• Sanchez-Aguilera, A., Montalban, C., de la Cueva, P., Sanchez-Verde, L., Morente, M. M., Garcia-Cosio, M., Garcia-Larana, J., Bellas, C., Provencio, M., Romagosa, V., de Sevilla, A. F., Menarguez, J., Sabin, P., Mestre, M. J., Mendez, M., Fresno, M. F., Nicolas, C., Piris, M. A., Garcia, J. F., for the Spanish Hodgkin Lymphoma Study Group, (2006). Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108: 662-668 [Abstract] [Full Text]  
• Noordijk, E. M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A. D.G., Kluin-Nelemans, J. C., Tirelli, U., Monconduit, M., Thomas, J., Eghbali, H., Aleman, B. M.P., Bosq, J., Vovk, M., Verschueren, T. A.M., Peny, A.-M., Girinsky, T., Raemaekers, J. M.M., Henry-Amar, M. (2006). Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. JCO 24: 3128-3135 [Abstract] [Full Text]  
• Ferme, C., Mounier, N., Casasnovas, O., Brice, P., Divine, M., Sonet, A., Bouafia, F., Bastard-Stamatoullas, A., Bordessoule, D., Voillat, L., Reman, O., Blanc, M., Gisselbrecht, C., for the Groupe d'Etude des Lymphomes de l'Adulte, (2006). Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 107: 4636-4642 [Abstract] [Full Text]  
• Foltz, L. M., Song, K. W., Connors, J. M. (2006). Hodgkin's Lymphoma in Adolescents. JCO 24: 2520-2526 [Abstract] [Full Text]  
• Hentrich, M., Maretta, L., Chow, K. U., Bogner, J. R., Schurmann, D., Neuhoff, P., Jager, H., Reichelt, D., Vogel, M., Ruhnke, M., Oette, M., Weiss, R., Rockstroh, J., Arasteh, K., Mitrou, P. (2006). Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 17: 914-919 [Abstract] [Full Text]  
• Schonfeld, S. J., Gilbert, E. S., Dores, G. M., Lynch, C. F., Hodgson, D. C., Hall, P., Storm, H., Andersen, A., Pukkala, E., Holowaty, E., Kaijser, M., Andersson, M., Joensuu, H., Fossa, S. D., Allan, J. M., Travis, L. B. (2006). Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients. JNCI J Natl Cancer Inst 98: 215-218 [Abstract] [Full Text]  
• Gobbi, P. G., Broglia, C., Levis, A., La Sala, A., Valentino, F., Chisesi, T., Sacchi, S., Corbella, F., Cavanna, L., Iannitto, E., Pavone, V., Molica, S., Corazza, G. R., Federico, M. (2006). MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors. Clin. Cancer Res. 12: 529-535 [Abstract] [Full Text]  
• Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., Berthelsen, A. K., Specht, L. (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107: 52-59 [Abstract] [Full Text]  
• Gobbi, P. G., Levis, A., Chisesi, T., Broglia, C., Vitolo, U., Stelitano, C., Pavone, V., Cavanna, L., Santini, G., Merli, F., Liberati, M., Baldini, L., Deliliers, G. L., Angelucci, E., Bordonaro, R., Federico, M. (2005). ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. JCO 23: 9198-9207 [Abstract] [Full Text]  
• Johnson, P. W.M., Radford, J. A., Cullen, M. H., Sydes, M. R., Walewski, J., Jack, A. S., MacLennan, K. A., Stenning, S. P., Clawson, S., Smith, P., Ryder, D., Hancock, B. W. (2005). Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). JCO 23: 9208-9218 [Abstract] [Full Text]  
• Carde, P. (2005). The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side?. JCO 23: 9058-9062 [Full Text]  
• Klimm, B., Reineke, T., Haverkamp, H., Behringer, K., Eich, H. T., Josting, A., Pfistner, B., Diehl, V., Engert, A. (2005). Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group. JCO 23: 8003-8011 [Abstract] [Full Text]  
• Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V., Engert, A. (2005). Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group. JCO 23: 7555-7564 [Abstract] [Full Text]  
• Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., Ansell, S. M. (2005). Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma. JCO 23: 7614-7620 [Abstract] [Full Text]  
• Hagler, K. T., Lynch, J. W. Jr (2005). Potential Influence of Health Systems in Accrual to Clinical Trials in Lymphoma. JCO 23: 7244-7245 [Full Text]  
• Connors, J. M. (2005). State-of-the-Art Therapeutics: Hodgkin's Lymphoma. JCO 23: 6400-6408 [Abstract] [Full Text]  
• Reinhardt, M. J., Herkel, C., Altehoefer, C., Finke, J., Moser, E. (2005). Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?. Ann Oncol 16: 1524-1529 [Abstract] [Full Text]  
• Shimabukuro-Vornhagen, A., Haverkamp, H., Engert, A., Balleisen, L., Majunke, P., Heil, G., Eich, H. T., Stein, H., Diehl, V., Josting, A. (2005). Lymphocyte-Rich Classical Hodgkin's Lymphoma: Clinical Presentation and Treatment Outcome in 100 Patients Treated Within German Hodgkin's Study Group Trials. JCO 23: 5739-5745 [Abstract] [Full Text]  
• Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K., Diehl, V. (2005). Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group. JCO 23: 5052-5060 [Abstract] [Full Text]  
• Schnell, R., Dietlein, M., Staak, J. O., Borchmann, P., Schomaecker, K., Fischer, T., Eschner, W., Hansen, H., Morschhauser, F., Schicha, H., Diehl, V., Raubitschek, A., Engert, A. (2005). Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody. JCO 23: 4669-4678 [Abstract] [Full Text]  
• Weihrauch, M. R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V., Bohlen, H., Wolf, J., Schultze, J. L. (2005). Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor. Cancer Res. 65: 5516-5519 [Abstract] [Full Text]  
• Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., Timothy, A. R. (2005). Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16: 1160-1168 [Abstract] [Full Text]  
• Re, D., Thomas, R. K., Behringer, K., Diehl, V. (2005). From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 105: 4553-4560 [Abstract] [Full Text]  
• Hohaus, S., Di Ruscio, A., Di Febo, A., Massini, G., D'Alo', F., Guidi, F., Mansueto, G., Voso, M. T., Leone, G. (2005). Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma. Clin. Cancer Res. 11: 2175-2179 [Abstract] [Full Text]  
• Ballova, V., Ruffer, J.-U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H. K., Duhmke, E., Worst, P., Wilhelmy, M., Naumann, R., Hentrich, M., Eich, H. T., Josting, A., Loffler, M., Diehl, V., Engert, A. (2005). A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16: 124-131 [Abstract] [Full Text]  
• Connors, J. M. (2005). Evolving Approaches to Primary Treatment of Hodgkin Lymphoma. ASH Education Book 2005: 239-244 [Abstract] [Full Text]  
• Engel, C., Scholz, M., Loeffler, M. (2004). A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 104: 2323-2331 [Abstract] [Full Text]  
• Czyz, J., Dziadziuszko, R., Knopinska-Postuszuy, W., Hellmann, A., Kachel, L., Holowiecki, J., Gozdzik, J., Hansz, J., Avigdor, A., Nagler, A., Osowiecki, M., Walewski, J., Mensah, P., Jurczak, W., Skotnicki, A., Sedzimirska, M., Lange, A., Sawicki, W., Sulek, K., Wach, M., Dmoszynska, A., Kus, A., Robak, T., Warzocha, K. (2004). Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 15: 1222-1230 [Abstract] [Full Text]  
• Bredenfeld, H., Franklin, J., Nogova, L., Josting, A., Fries, S., Mailander, V., Oertel, J., Diehl, V., Engert, A. (2004). Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group. JCO 22: 2424-2429 [Abstract] [Full Text]  
• Bendandi, M., Pileri, S. A., Zinzani, P. L. (2004). Challenging paradigms in lymphoma treatment. Ann Oncol 15: 703-711 [Full Text]  
• Schrader, C., Janssen, D., Kneba, M., Lennert, K. (2004). A 38-Year History of Natural-Killer-Cell Lymphoma. NEJM 350: 418-419 [Full Text]  
• Diehl, V. (2004). Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease. JCO 22: 15-18 [Full Text]  
• Maignan, C. l., Desablens, B., Delwail, V., Dib, M., Berthou, C., Vigier, M., Ghandour, C., Atmani, S., Casassus, P., Maisonneuve, H., Mevel, A. L., Traulle, C., Bernard, M., Briere, J., Colonna, P., Andrieu, J.-M. (2004). Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103: 58-66 [Abstract] [Full Text]  
• Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Duhmke, E., Willich, N., Muller, R.-P., Schmidt, B. F., Renner, H., Muller-Hermelink, H. K., Pfistner, B., Wolf, J., Hasenclever, D., Loffler, M., Diehl, V. (2003). Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. JCO 21: 3601-3608 [Abstract] [Full Text]  
• Ekert, H., Diehl, V., Franklin, J. (2003). Chemotherapy for Hodgkin's Disease. NEJM 349: 1186-1187 [Full Text]  
• Diehl, V., Stein, H., Hummel, M., Zollinger, R., Connors, J. M. (2003). Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. ASH Education Book 2003: 225-247 [Abstract] [Full Text]